Lataa...
Use of Raloxifene and Tamoxifen by Breast Cancer Risk Level in a Medicare-1 eligible Cohort
BACKGROUND: Raloxifene and tamoxifen are FDA approved for breast cancer risk reduction; in 2013, the US Preventive Services Task Force (USPSTF) recommended these drugs for breast cancer risk reduction in high-risk women. Information on use of raloxifene and tamoxifen for breast cancer risk reduction...
Tallennettuna:
| Julkaisussa: | Am J Obstet Gynecol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5970073/ https://ncbi.nlm.nih.gov/pubmed/29630889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajog.2018.03.031 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|